Evaluación de la atención farmacéutica y del envío domiciliario de medicación a pacientes con leucemia mieloide crónica: proyecto TICAFAN / Evaluation of pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia - TICAFAN Project

OBJETIVO: Describir y analizar los resultados obtenidos con el desarrollo del proyecto "Tecnologías de la Información y la Comunicación adaptadas a la Atención Farmacéutica No presencial" (TICAFAN). Confirmar la validez del modelo para prestar atención farmacéutica a pacientes con leucemia mieloide crónica. MÉTODO: Estudio antes-después del cambio en el modelo de dispensación y de atención farmacéutica. Se analizó la evolución de la enfermedad, las intervenciones farmacéuticas, la adherencia al tratamiento, el número de dispensaciones realizadas mediante envío domiciliario y sus incidentes desde el 1 de febrero del 2014 al 31 de octubre del 2016. En mayo del 2015 se realizó una encuesta de satisfacción. RESULTADOS: Se incluyeron 21 pacientes en el programa, la edad media en el momento de inclusión fue de 55 años (DE 17). Se realizaron 470 envíos, con una disminución del 80% (DE 15) en los desplazamientos de los pacientes al hospital. Hubo 2 incidentes, por olvido de los pacientes del día del envío. Se registraron 49 intervenciones farmacéuticas y se atendieron 30 consultas a demanda fuera de las programadas, lo que supuso un mayor número de intervenciones que en el periodo anterior. No hubo diferencias en la adherencia antes y después de la inclusión en el programa. La respuesta se mantuvo en 9 pacientes, mejoró en otros 9 y empeoró en 3, recuperándose posteriormente. La satisfacción de los pacientes con el proyecto fue de 9,7 (DE 0,6) sobre 10. CONCLUSIONES: El proyecto TICAFAN ha conseguido mantener la atención farmacéutica a los pacientes incluidos en el mismo, la adherencia y la respuesta al tratamiento, evitando desplazamientos al hospital para la dispensación de medicación

OBJECTIVES: To describe and analyze the results of the development of the "Information and communications technology adapted to remote pharmaceutical care" (TICAFAN, by its Spanish acronym) project and confirm its validity to provide pharmaceutical care to chronic myelogenous leukemia patients. METHODS: Before and after study of a modified pharmaceutical care model. The course of the disease, pharmaceutical interventions, treatment adherence, and number of home deliveries and their incidents were analyzed from February 1, 2014 to October 31, 2016. A satisfaction survey was conducted in May 2015. RESULTS: Twenty one patients were included in the program until October 31, 2016. The mean age at the time of inclusion was 55 years (SD 17). There were 470 home deliveries, with an 80% (SD 15) reduction in the trips to the hospital. There were 2 incidents owing to the fact that the patients did not remember the shipment date. Forty nine pharmaceutical interventions were registered and 30 on-demand inquiries were answered, apart from the scheduled monthly consultations. This meant a greater number of interventions than in a previous period. There were no differences in adherence before and after the inclusion in the program. Response was maintained in 9 patients, improved in 9 and worsened, but recovered afterwards, in 3 patients. Patients gave the project a score of 9.7 (SD 0.6) out of 10. CONCLUSIONS: The TICAFAN project has managed to keep providing pharmaceutical care as well as to maintain adherence and treatment response, reducing hospital visits for drug collection

Conciliación de la medicación al ingreso: resultados e identificación de pacientes diana / Medication reconciliation at hospital admission: results and identification of target patients

Objetivo. Identificar y cuantificar las discrepancias entre el tratamiento prescrito al ingreso hospitalario y el tratamiento crónico del paciente. Identificar variables que puedan utilizarse en la selección de los pacientes más susceptibles de beneficiarse de un programa de conciliación de la medicación. Material y métodos. Se diseñó un estudio prospectivo de conciliación de la medicación al ingreso hospitalario en el servicio de cirugía vascular y angiología de marzo a diciembre de 2014. Al ingreso el personal de enfermería informaba al paciente del estudio y le solicitaban que recopilara información sobre su tratamiento crónico. Posteriormente, el personal farmacéutico revisaba el historial clínico, las prescripciones crónicas y entrevistaba al paciente para obtener la mejor historia farmacoterapéutica posible. Ésta se comparaba con la prescripción realizada al ingreso y las discrepancias se registraban en el evolutivo clínico. Finalmente, el personal médico clasificaba las discrepancias y modificaba la prescripción en caso necesario. Se compararon las características de los pacientes con y sin discrepancias no justificadas (DNJ) y se construyeron las curvas de característica operativa del receptor de aquellas con diferencias estadísticamente significativas, para determinar su sensibilidad y especificidad para seleccionar pacientes con DNJ. Resultados. Se incluyeron 380 pacientes, registrándose 845 DNJ, 600 justificadas no documentadas y 439 justificadas documentadas. Doscientos noventa y tres pacientes tuvieron al menos una DNJ (77%), 65 solo justificadas (17%) y 22 ninguna (6%). Las DNJ fueron: diferente dosis, vía o frecuencia (51%), omisión (39%), medicamento equivocado (8%) y comisión (2%). Las variables relacionadas con las discrepancias fueron número de medicamentos habituales y quién facilitaba la información. Conclusiones. En la mayoría de estudios la DNJ mayoritaria es la omisión, a diferencia de lo que ocurre en nuestro caso. La variable que permite seleccionar pacientes con mayor riesgo de presentar discrepancias es el número de medicamentos habituales. También aumenta el riesgo de sufrir DNJ cuando no es el propio paciente el que conoce y gestiona su tratamiento crónico (AU)

Objective. To quantify and to classify the discrepancies between the admission treatment and the usual patient treatment. To determine the variables that predict those patients that will have more benefit from medication reconciliation. Material and methods. A prospective medication reconciliation study was conducted in the Vascular Surgery Unit from March 2014 to December 2014. When the patients were admitted to the Vascular Surgery Unit, they were informed about the study and asked to prepare information about their chronic treatment. The pharmacist then checked their clinical records, outpatient prescriptions, and also interviewed the patient, obtaining the best pharmacotherapeutic history available. The discrepancies with the admission treatment were written into the patient electronic clinical records. Finally, the physician classified the discrepancies, and changed the treatment, if needed. The statistical analysis included a comparison between patients with and without a non-justified discrepancy (NJD). The statistically different characteristics were used to plot Receiver Operating Characteristic curves, in order to determine the sensitivity and the specificity of these variables to select patients with discrepancies. Results. A total of 380 patients were included. There were 845 non-justified, 600 justified non-documented, and 439 justified documented discrepancies. At least one NJD was identified in 293 patients (77%), with 65 patients (17%) having only justified discrepancies, and 22 patients (6%) having no discrepancies. NJD were: different dose, route or schedule (51%), omission (39%), wrong drug (8%) and commission (2%). The variables associated with discrepancies were number of chronic medications drugs and provider of information. Conclusions. In most studies, omission is the most frequent error. In contrast, in our study the most frequent error is different dose, route, or schedule. The variable that allows selecting patients at higher risk of discrepancies is the number of chronic drugs. This risk is also increased if the patients are not the manager of their own medication (AU)

[Medication reconciliation at hospital admission: Results and identification of target patients]. / Conciliación de la medicación al ingreso: resultados e identificación de pacientes diana.

OBJECTIVE: To quantify and to classify the discrepancies between the admission treatment and the usual patient treatment. To determine the variables that predict those patients that will have more benefit from medication reconciliation. MATERIAL AND METHODS: A prospective medication reconciliation study was conducted in the Vascular Surgery Unit from March 2014 to December 2014. When the patients were admitted to the Vascular Surgery Unit, they were informed about the study and asked to prepare information about their chronic treatment. The pharmacist then checked their clinical records, outpatient prescriptions, and also interviewed the patient, obtaining the best pharmacotherapeutic history available. The discrepancies with the admission treatment were written into the patient electronic clinical records. Finally, the physician classified the discrepancies, and changed the treatment, if needed. The statistical analysis included a comparison between patients with and without a non-justified discrepancy (NJD). The statistically different characteristics were used to plot Receiver Operating Characteristic curves, in order to determine the sensitivity and the specificity of these variables to select patients with discrepancies. RESULTS: A total of 380 patients were included. There were 845 non-justified, 600 justified non-documented, and 439 justified documented discrepancies. At least one NJD was identified in 293 patients (77%), with 65 patients (17%) having only justified discrepancies, and 22 patients (6%) having no discrepancies. NJD were: different dose, route or schedule (51%), omission (39%), wrong drug (8%) and commission (2%). The variables associated with discrepancies were number of chronic medications drugs and provider of information. CONCLUSIONS: In most studies, omission is the most frequent error. In contrast, in our study the most frequent error is different dose, route, or schedule. The variable that allows selecting patients at higher risk of discrepancies is the number of chronic drugs. This risk is also increased if the patients are not the manager of their own medication.